The present armamentarium of endoscopic hemostatic therapy for non-variceal upper gastrointestinal hemorrhage includes injection,electrocautery and clips.There are newer endoscopic options such as hemostatic sprays,en...The present armamentarium of endoscopic hemostatic therapy for non-variceal upper gastrointestinal hemorrhage includes injection,electrocautery and clips.There are newer endoscopic options such as hemostatic sprays,endoscopic suturing and modifications of current options including coagulation forceps and over-the-scope clips.Peptic hemorrhage is the most prevalent type of nonvariceal upper gastrointestinal hemorrhage and traditional endoscopic interventions have demonstrated significant hemostasis success.However,the hemostatic success rate is less for other entities such as Dieulafoy’s lesions and bleeding from malignant lesions.Novel innovations such as endoscopic submucosal dissection and peroral endoscopic myotomy has spawned a need for dependable hemostasis.Gastric antral vascular ectasias are associated with chronic gastrointestinal bleeding and usually treated by standard argon plasma coagulation (APC),but newer modalities such as radiofrequency ablation,banding,cryotherapy and hybrid APC have been utilized as well.We will opine on whether the newer hemostatic modalities have generated success when traditional modalities fail and should any of these modalities be routinely available in the endoscopic toolbox.展开更多
目的系统评价特利加压素联合生长抑素治疗肝硬化上消化道出血的疗效及安全性。方法检索自建库至2023年7月在PubMed、Cochrane Library、Embase、Web of Science、中国知网(CNKI)、万方数据库、维普数据库(VIP)、中国生物医学文献数据库(...目的系统评价特利加压素联合生长抑素治疗肝硬化上消化道出血的疗效及安全性。方法检索自建库至2023年7月在PubMed、Cochrane Library、Embase、Web of Science、中国知网(CNKI)、万方数据库、维普数据库(VIP)、中国生物医学文献数据库(SinoMed)等发表的关于特利加压素联合生长抑素治疗肝硬化上消化道出血的随机对照试验(RCTs),试验组采用特利加压素联合生长抑素,对照组单用生长抑素。采用Revman5.3和Stata17软件对全因死亡率、总体有效率、不良事件发生率、止血时间、输血量和住院时间进行Meta分析。结果纳入20项RCTs,共计1502例患者。Meta分析结果显示:与对照组相比,试验组治疗肝硬化上消化道出血可降低全因死亡率(OR=0.34,95%CI:0.19~0.59,P<0.01)和输血量(SMD=-2.29,95%CI:-3.13~-1.46,P<0.01),缩短止血时间(SMD=-1.64,95%CI:-2.03~-1.25,P<0.01)和住院时间(MD=-7.12,95%CI:-7.47~-6.77,P<0.01),提高总体有效率(OR=3.50,95%CI:2.46~4.97,P<0.01);而不良事件的发生率比较差异无统计学意义(OR=1.20,95%CI:0.82~1.75,P=0.34)。结论现有证据表明,与单用生长抑素相比,特利加压素联合生长抑素治疗肝硬化上消化道出血可显著提高总体有效率,降低死亡风险和输血量,缩短止血时间及住院时间,且不增加不良反应。展开更多
目的探讨生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血(upper gastrointestinal bleeding,UGIB)的临床效果。方法选取138例肝硬化合并UGIB患者为受试对象,按照随机数字表分为试验组与对照组每组69例。对照组给予生长抑素,试验组在...目的探讨生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血(upper gastrointestinal bleeding,UGIB)的临床效果。方法选取138例肝硬化合并UGIB患者为受试对象,按照随机数字表分为试验组与对照组每组69例。对照组给予生长抑素,试验组在其基础上联合泮托拉唑进行治疗。比较治疗前及治疗24、48、72 h后,两组急性时相反应程度:血清超敏C反应蛋白(hsCRP)、UGIB危急程度[Glasgow-Blatchford评分系统(GBS)]、血红蛋白(Hb)水平变化,分析治疗72 h后两组治疗效果、转归情况及疗程内药物不良反应发生率差异。结果治疗24、48、72 h后,两组血清hsCRP水平及GBS评分均较治疗前明显下降,且试验组明显低于同期对照组,差异均有统计学意义( P <0.05;试验组Hb水平与治疗前比较差异无统计学意义( P >0.05),但均明显高于同期对照组,差异均有统计学意义( P <0.05)。治疗72 h后,试验组治疗效果明显优于对照组,差异有统计学意义( P <0.05)。试验组输血量、止血时间、血尿素氮(BUN)恢复正常时间、转内镜治疗例数及住院时间均明显少于对照组,差异均有统计学意义( P <0.05),但两组二次出血例数比较差异无统计学意义( P >0.05)。疗程内,两组各项药物不良反应发生率比较差异均无统计学意义( P >0.05)。结论生长抑素联合泮托拉唑应用于肝硬化合并UGIB能获得较理想的治疗效果,其药物不良反应发生率与单药相近,安全性较突出。展开更多
文摘The present armamentarium of endoscopic hemostatic therapy for non-variceal upper gastrointestinal hemorrhage includes injection,electrocautery and clips.There are newer endoscopic options such as hemostatic sprays,endoscopic suturing and modifications of current options including coagulation forceps and over-the-scope clips.Peptic hemorrhage is the most prevalent type of nonvariceal upper gastrointestinal hemorrhage and traditional endoscopic interventions have demonstrated significant hemostasis success.However,the hemostatic success rate is less for other entities such as Dieulafoy’s lesions and bleeding from malignant lesions.Novel innovations such as endoscopic submucosal dissection and peroral endoscopic myotomy has spawned a need for dependable hemostasis.Gastric antral vascular ectasias are associated with chronic gastrointestinal bleeding and usually treated by standard argon plasma coagulation (APC),but newer modalities such as radiofrequency ablation,banding,cryotherapy and hybrid APC have been utilized as well.We will opine on whether the newer hemostatic modalities have generated success when traditional modalities fail and should any of these modalities be routinely available in the endoscopic toolbox.
文摘目的系统评价特利加压素联合生长抑素治疗肝硬化上消化道出血的疗效及安全性。方法检索自建库至2023年7月在PubMed、Cochrane Library、Embase、Web of Science、中国知网(CNKI)、万方数据库、维普数据库(VIP)、中国生物医学文献数据库(SinoMed)等发表的关于特利加压素联合生长抑素治疗肝硬化上消化道出血的随机对照试验(RCTs),试验组采用特利加压素联合生长抑素,对照组单用生长抑素。采用Revman5.3和Stata17软件对全因死亡率、总体有效率、不良事件发生率、止血时间、输血量和住院时间进行Meta分析。结果纳入20项RCTs,共计1502例患者。Meta分析结果显示:与对照组相比,试验组治疗肝硬化上消化道出血可降低全因死亡率(OR=0.34,95%CI:0.19~0.59,P<0.01)和输血量(SMD=-2.29,95%CI:-3.13~-1.46,P<0.01),缩短止血时间(SMD=-1.64,95%CI:-2.03~-1.25,P<0.01)和住院时间(MD=-7.12,95%CI:-7.47~-6.77,P<0.01),提高总体有效率(OR=3.50,95%CI:2.46~4.97,P<0.01);而不良事件的发生率比较差异无统计学意义(OR=1.20,95%CI:0.82~1.75,P=0.34)。结论现有证据表明,与单用生长抑素相比,特利加压素联合生长抑素治疗肝硬化上消化道出血可显著提高总体有效率,降低死亡风险和输血量,缩短止血时间及住院时间,且不增加不良反应。
文摘目的探讨生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血(upper gastrointestinal bleeding,UGIB)的临床效果。方法选取138例肝硬化合并UGIB患者为受试对象,按照随机数字表分为试验组与对照组每组69例。对照组给予生长抑素,试验组在其基础上联合泮托拉唑进行治疗。比较治疗前及治疗24、48、72 h后,两组急性时相反应程度:血清超敏C反应蛋白(hsCRP)、UGIB危急程度[Glasgow-Blatchford评分系统(GBS)]、血红蛋白(Hb)水平变化,分析治疗72 h后两组治疗效果、转归情况及疗程内药物不良反应发生率差异。结果治疗24、48、72 h后,两组血清hsCRP水平及GBS评分均较治疗前明显下降,且试验组明显低于同期对照组,差异均有统计学意义( P <0.05;试验组Hb水平与治疗前比较差异无统计学意义( P >0.05),但均明显高于同期对照组,差异均有统计学意义( P <0.05)。治疗72 h后,试验组治疗效果明显优于对照组,差异有统计学意义( P <0.05)。试验组输血量、止血时间、血尿素氮(BUN)恢复正常时间、转内镜治疗例数及住院时间均明显少于对照组,差异均有统计学意义( P <0.05),但两组二次出血例数比较差异无统计学意义( P >0.05)。疗程内,两组各项药物不良反应发生率比较差异均无统计学意义( P >0.05)。结论生长抑素联合泮托拉唑应用于肝硬化合并UGIB能获得较理想的治疗效果,其药物不良反应发生率与单药相近,安全性较突出。
